Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Mental Health & Depression — Weekly Report — September 28, 2026

Home/Health Insights/Mental Health & Depression — September 28 – October 5, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Mental Health & Depression
Updated Monday · November 16, 2026
Mental Health & Depression · September 28 – October 5, 2026

Mental Health & Depression
Weekly Report

This week's data 71 new clinical trials registered across 10 countries, with 3,257 trials actively recruiting patients worldwide.
Week of September 28 – October 5, 2026
  • 71 new clinical trials registered across 10 countries.
  • 3,257 trials actively recruiting patients worldwide.
  • Notable trial: Social Contact-Based Brief Video Interventions To Reduce Stigma and ImproVe Engagement in HIV Prevention and Care and... (3900 patients).
  • 2,069 new research papers published.
  • Drug safety: Most reported effect across tracked medications (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine) was Off Label Use.
  • 8 active drug recall alert(s) — see details below.

The week in numbers

Figures · September 28 – October 5, 2026
New Trials This Week
71.
registered Sep 28–Oct 5
Recruiting Now
3,257
active trials seeking patients
Countries
10
with active trials this week
Papers Published
2,069
new studies this week
Phase 3 Trials
1
late-stage trials this week
Fig. 01

Trials by country

Count · September 28 – October 5, 2026
United States
20
Turkey (Türkiye)
13
Not specified
9
Germany
9
France
5
United Kingdom
2
Egypt
2
Jordan
2
South Korea
2
Iran
1
0 5 10 15 20
total
Fig. 02

Trials by phase

Distribution · September 28 – October 5, 2026

New clinical trials registered this week for Mental Health & Depression. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

71 trials registered for Mental Health & Depression. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 A Study of Music Therapy for Anxiety in People With Cancer Mental Health & Depression · Memorial Sloan Kettering Cancer Center (NCT07845422) Other Recruiting 240 United States
02 Effect of Virtual Reality on Pain and Anxiety in Women With Dysmenorrhea: A Randomized Controlled Trial Mental Health & Depression · Tokat Gaziosmanpasa University (NCT07853508) Other Not Yet Recruiting 68 Turkey (Türkiye)
03 Effect of a Social-Support-Based Educational Intervention on COVID-19-Related Anxiety and Perceived Social Support in Pregnant Women: A Randomized Pretest-Posttest Controlled Trial Mental Health & Depression · Atefeh Dehnoalian (NCT07856576) Other Completed 110 Iran
04 Predictors of Treatment Outcome in Major Depressive Disorder Mental Health & Depression · Assiut University (NCT07853365) Other Not Yet Recruiting 100 N/A
05 Music Intervention to Reduce Anxiety and Prevent Delirium in Older Adults Undergoing Cardiac Surgery Mental Health & Depression · KU Leuven (NCT07851194) Other Not Yet Recruiting 256 Belgium
06 HBOT Effects on First Responders' Cognition and Well-Being Mental Health & Depression · Summit Hyperbarics and Wellness (NCT07852728) Phase 2 Recruiting 54 United States
07 Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Depression (Trial 2 of 3) Mental Health & Depression · State University of New York at Buffalo (NCT07854301) Other Not Yet Recruiting 100 United States
08 Preoperative Music Intervention for Anxiety in Hip and Knee Arthroplasty Mental Health & Depression · Columbia University (NCT07845695) Other Recruiting 52 United States
09 Natural Sound Therapy on Procedural Pain and Anxiety During Negative Pressure Wound Therapy Dressing Changes Mental Health & Depression · University of Basrah (NCT07854717) Other Not Yet Recruiting 150 Iraq
10 Virtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury Mental Health & Depression · Istanbul Physical Medicine Rehabilitation Training and Research Hospital (NCT07846410) Other Not Yet Recruiting 40 Turkey (Türkiye)
11 Scenario-Based Hybrid Simulation for Patient Education in Assisted Reproductive Treatment Mental Health & Depression · Duzce University (NCT07851155) Other Not Yet Recruiting 30 N/A
12 The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With Lung Cancer Mental Health & Depression · Izmir Bakircay University (NCT07847138) Other Completed 50 Turkey (Türkiye)
13 Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker Study Mental Health & Depression · Summit Hyperbarics and Wellness (NCT07849465) Phase 2 Recruiting 34 United States
14 PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood Mental Health & Depression · University of Oxford (NCT07848477) Other Not Yet Recruiting 60 United Kingdom
15 Pain Perception After Manual and Ultrasonic Periodontal Debridement in Patients With Gingivitis Mental Health & Depression · Recep Tayyip Erdogan University (NCT07847736) Other Completed 206 Turkey (Türkiye)
16 COMPARISON OF THE TOPICAL ANAESTHETIC EFFICACY OF VARIOUS AGENTS WITH ANAESTHETIC EFFECTS IN CHILDREN Mental Health & Depression · Uşak University (NCT07849192) Other Completed 50 Turkey (Türkiye)
17 Brave Heart Intervention and Mental Health Outcomes Among Young People in Sierra Leone Mental Health & Depression · Slum and Rural Health Initiative (NCT07853092) Other Completed 2,244 Sierra Leone
18 Effect of TMS Treatment on Defense Mechanisms and Functionality in Patients With Depression Mental Health & Depression · Namik Kemal University (NCT07853989) Other Not Yet Recruiting 50 Turkey (Türkiye)
19 The Effect of a Mandala Coloring-Based Nursing Intervention on Perceived Nursing Image and Anxiety in Children Hospitalized in a Pediatric Clinic: A Randomized Controlled Trial Mental Health & Depression · Artvin Coruh University (NCT07845123) Other Recruiting 64 Turkey (Türkiye)
20 The Effect of Virtual Reality Headsets on Pain, Anxiety, Patient Satisfaction, and Physiological Parameters in Patients Undergoing Open-Heart Surgery Mental Health & Depression · Dokuz Eylul University (NCT07843511) Other Not Yet Recruiting 44 Turkey (Türkiye)
21 Youth Overdose & Use Reduction in Rural Systems Mental Health & Depression · Seattle Children's Hospital (NCT07846735) Other Not Yet Recruiting 550 N/A
22 The Impact of Overnight Active Temperature Regulation on Gut Microbiome, Inflammation, and Circadian Rhythm. Mental Health & Depression · Eight Sleep Inc. (NCT07848594) Other Recruiting 100 United States
23 iTBS Versus Standard 10 Hz rTMS for Treatment-Resistant Depression (TRD) Mental Health & Depression · Kafrelsheikh University (NCT07852065) Other Active Not Recruiting 182 Egypt
24 Arts for Wellness (AFW): Arts-Based Social Prescribing During Inpatient Rehabilitation for Older Adults in Singapore Mental Health & Depression · SingHealth Community Hospitals (NCT07851467) Other Completed 288 Singapore
25 Classical and Heavy Metal Music Effects on Stress Among Medical Students Mental Health & Depression · University of Sharjah (NCT07848503) Other Completed 300 United Arab Emirates
26 ACT for Dementia Caregivers: Evaluating Psychological Flexibility as the Mechanism to Improve Psychological Distress Mental Health & Depression · Utah State University (NCT07845032) Other Recruiting 120 United States
27 Effects of Basic Body Awareness Therapy Added to Aerobic Exercise in Women With Fibromyalgia Mental Health & Depression · Hacer Önen Tekin (NCT07851896) Other Not Yet Recruiting 40 N/A
28 Multisensory Approaches for Managing Pediatric Dental Anxiety Mental Health & Depression · Bezmialem Vakif University (NCT07848542) Other Recruiting 60 Turkey (Türkiye)
29 Assessment of the Frequency of Functional Neurological Disorders in Multiple Sclerosis and Analysis of Clinical and Psychological Determinants: A Multicenter Cross-Sectional Study Mental Health & Depression · University Hospital, Strasbourg, France (NCT07849816) Other Not Yet Recruiting 100 N/A
30 Focused Ultrasound for Behavioral Health Mental Health & Depression · Attune Neurosciences Inc (NCT07851038) Other Not Yet Recruiting 300 United States
31 ImprovINg the TIMEly Diagnosis and Treatment of Cancer and Cardio-metabolic Diseases in People With Mental Disorders: Reducing Health Disparities Through Integrated Care Mental Health & Depression · IRCCS San Raffaele (NCT07843433) Other Not Yet Recruiting 120 N/A
32 Validation of an Algorithm for Predicting Awakenings Associated With Trauma-related Nightmares, Based on the Analysis of Physiological Patterns in Military and Former Military Patients Suffering From Post-traumatic Stress Disorder Mental Health & Depression · Direction Centrale du Service de Santé des Armées (NCT07851480) Other Recruiting 27 France
33 Evaluation of a Prehabilitation Program in Patients Requiring Scoliosis Surgery. Mental Health & Depression · University Hospital, Grenoble (NCT07852286) Other Not Yet Recruiting 60 France
34 A Real-world Study of Gastrointestinal Health and Mental Wellness in U.S. Adults Following 12 Weeks of Probiotic Supplementation. Mental Health & Depression · Novonesis (NCT07849036) Other Not Yet Recruiting 300 United Kingdom
35 Effect of Psychosocial Intervention on Body Image, Self Esteem, Burn Anxiety and Depression Among Patients With Burn Mental Health & Depression · Ain Shams University (NCT07853794) Other Completed 128 Egypt
36 Effects of Antenatal Nutrition Counseling on Maternal and Infant Outcomes Mental Health & Depression · Eastern Mediterranean University (NCT07845773) Other Completed 108 Cyprus
37 Interactive Effects of Early-Life Stress, Diet, and Metabolism on Gastrointestinal Dysfunction With Neuropsychiatric Symptoms Mental Health & Depression · Shandong University (NCT07852819) Other Not Yet Recruiting 200 N/A
38 Virtual Reality to Reduce Anxiety in Adults Having Lower Wisdom Tooth Surgery Mental Health & Depression · Hanoi Medical University (NCT07853014) Other Recruiting 120 Vietnam
39 Ultra-Processed Foods, DASH Diet, and Well-Being in Severe Mental Illness Mental Health & Depression · Abant Izzet Baysal University (NCT07844837) Other Completed 105 Turkey (Türkiye)
40 Artificial Intelligence-Based Virtual Reality on Patient With Upper Gastrointestinal Endoscopy Mental Health & Depression · Al-Zaytoonah University of Jordan (NCT07848009) Other Completed 500 Jordan
41 Parenting-STAIR Modular for Military Fathers and OCONUS Families Mental Health & Depression · New York University (NCT07843654) Other Not Yet Recruiting 243 United States
42 Study of Individual Neurocognitive Changes Associated With the Training of the Working Memory. Mental Health & Depression · Centre Hospitalier St Anne (NCT07851051) Other Recruiting 8 France
43 Social Contact-Based Brief Video Interventions To Reduce Stigma and ImproVe Engagement in HIV Prevention and Care and Mental Health Care for Youth Living With and Vulnerable to HIV Mental Health & Depression · City University of New York, School of Public Health (NCT07851077) Other Not Yet Recruiting 3,900 N/A
44 Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression. Mental Health & Depression · Charite University, Berlin, Germany (NCT07843927) Phase 3 Recruiting 320 Germany
45 Personalized Accelerated iTBS Versus Sham for Major Depressive Disorder Mental Health & Depression · Capital Medical University (NCT07843875) Other Not Yet Recruiting 90 N/A
46 The Effect of Virtual Reality Application on Pain, Anxiety, and Embarrassment During Colonoscopy Mental Health & Depression · Kocaeli University (NCT07853300) Other Enrolling By Invitation 76 Turkey (Türkiye)
47 The Effect of Using a Stress Ball on Pain, Anxiety, and Vital Signs During Breast Biopsy Mental Health & Depression · TC Erciyes University (NCT07844395) Other Recruiting 53 Turkey (Türkiye)
48 Effectiveness of a Nurse-facilitated Artificial Intelligence Chatbot on Psychological Well-being and Mental Health Stigma Among Patients With Psychiatric Disorders: A Quasi-experimental Study Mental Health & Depression · Al-Zaytoonah University of Jordan (NCT07848022) Other Completed 72 Jordan
49 Enhancing Occupational Therapy Graduate Student Well-Being Mental Health & Depression · Lauren Newhouse (NCT07846085) Other Completed 63 United States
50 Digital Tai Chi Intervention on Physical Fitness, Anxiety, Depression and Stress Among College Students Mental Health & Depression · Xin Liu (NCT07854821) Other Active Not Recruiting 56 China
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Mental Health & Depression. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
sertraline Nausea 958
fluoxetine Off Label Use 508
escitalopram Fatigue 725
venlafaxine Off Label Use 734
duloxetine Nausea 909

Recalls & safety notices

§ 05 · 8 items this week

FDA drug recall notices for medications related to Mental Health & Depression. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionU.S Nationwide StatusOngoing
Jul 15
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionNationwide in the US StatusOngoing
Dec 6
2024
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc DistributionUS Nationwide. StatusOngoing
Apr 14
2025
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNJ, AZ, IN StatusOngoing
Jul 25
2025
IIClass

DULOXETINE

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

ManufacturerAjanta Pharma Ltd. DistributionNationwide within U.S StatusOngoing
Apr 29
2026
IIClass

DULOXETINE HYDROCHLORIDE

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

ManufacturerBreckenridge Pharmaceutical, Inc. DistributionNationwide within the United States StatusOngoing
Nov 24
2025
§ 06

Published research

2,069 papers

Recently published peer-reviewed studies related to Mental Health & Depression, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Experiences of Intensive Care Nurses in Their Practice of Physical Restraint Among Patients: A Qualitative Study. Uludağ E et al. 10.1002/nop2.70799
View abstract

INTRODUCTION: Although physical restraint causes mental and physical harm to patients, such practice occurs worldwide to ensure patient safety. It is non-standard practice for a number of reasons, including the lack of education, training, and protocol. OBJECTIVE: This study aims to determine the experiences of nurses who apply physical restraint to patients. METHODS: A descriptive phenomenological method was employed in this study, wherein semi-structured interviews were the data collection method. In this qualitative study, the data consisted of semi-structured individual interviews with nurses (n = 20). The data were analysed phenomenologically and were arranged with MAXqda 22 analysis software. The study complies with the COREQ checklist. RESULTS: Six main themes were found from the data. The themes were (i) experiences related to nurses' physical restraint procedures, (ii) ethical balance in nursing, (iii) nurses' emotions, (iv) the meaning of physical restraint, (v) nurses' observations regarding patients' reactions to physical restraints, and (vi) the experience of ethical dilemmas. The nurses perceived physical restraint as being uncomfortable, a necessity or an obligation, as beneficial for patients, and a practice seen as punishment. CONCLUSIONS: The findings showed that physical restraint elicited diverse thoughts and emotions among nurses, who reported difficulties in coping with these emotions and insufficient knowledge of restraint procedures. Nurses also described the need to protect patient safety while preserving patient autonomy, highlighting the ethical balance involved in decisions concerning physical restraint. IMPLICATIONS FOR NURSING PRACTICE: This study has provided insight that can guide clinician nurses, educators, and policy-makers in improving physical restraint administration. The lack of knowledge held among nurses as to physical restraint procedures emphasizes the importance of education and training on this topic and can suggest areas of development for pertinent policies and guidelines. PATIENT OR PUBLIC CONTRIBUTION: No patient or public contribution.

Nursing open 2026 Oct PubMed
02 Transdiagnostic patterns of electroencephalography (EEG)-derived aperiodic activity across schizophrenia-spectrum, bipolar, and depressive disorders: A systematic review. Le GH et al. 10.1111/pcn.70143
View abstract

Aperiodic electroencephalographic activity is proposed as a scalable marker of cortical population dynamics relevant to excitation-inhibition balance. However, it remains unclear whether aperiodic parameters represent disorder-specific abnormalities or context-sensitive indices of clinically relevant brain states. Consistent with systematic-review guidelines and a prospectively registered protocol, Ovid databases and PubMed were searched from inception through February 9, 2026, with updated manual searching conducted through July 14, 2026. Peer-reviewed studies reporting electroencephalography-derived aperiodic parameters in adults with schizophrenia-spectrum disorders, major depressive disorder, treatment-resistant depression, and/or bipolar disorder were eligible. Studies lacking aperiodic outcomes or separable findings for eligible diagnoses were excluded. Two reviewers independently conducted study screening, data extraction, and risk-of-bias assessments. Findings were synthesized narratively by diagnosis, recording context, and parameter. Thirty articles (N = 2298 aggregate participants) spanning cross-sectional, longitudinal, and interventional designs were included. Findings in schizophrenia-spectrum disorders were heterogeneous, with several studies reporting steeper slopes, higher offsets, or reduced temporal flexibility relative to healthy controls. Task-related and dynamic measures often showed greater clinical relevance than static resting-state parameters. Studies of major depressive disorder and treatment-resistant depression more consistently reported flatter slopes and reduced offsets, particularly in central and posterior regions, with evidence from sleep and intracranial recordings. Aperiodic parameters were sensitive to treatment-related modulation, although the direction of change differed across interventions. Bipolar disorder evidence was limited, and methodological heterogeneity precluded quantitative synthesis. Aperiodic electroencephalographic activity may be more informative as a context-sensitive, within-subject marker of cortical state and treatment-related change than a fixed diagnostic signature. Methodological harmonization and direct physiological validation remain necessary before clinical implementation.

Psychiatry and clinical neurosciences 2026 Oct 4 PubMed
03 Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial. Wang Y et al. 10.1080/07853890.2026.2740294
View abstract

BACKGROUND: Evidence regarding repeated remimazolam administration remains limited. We hypothesized that remimazolam would be associated with fewer adverse events than propofol while maintaining stable sedative requirements across three repeated sedation sessions. METHODS: Patients with cervical cancer undergoing three fractions of interstitial brachytherapy were randomized to propofol or remimazolam. The primary outcome was the proportion of sedation episodes with at least one prespecified intraoperative adverse event across three sessions. Secondary outcomes included sedative dose, hemodynamics, and sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI) and Athens Insomnia Scale (AIS). RESULTS: A total of 100 participants were randomized, of whom 91 completed all three prespecified sedation sessions and were included in the primary per-protocol analysis (46 in the propofol group and 45 in the remimazolam group). Across 138 propofol and 135 remimazolam episodes, overall adverse events were less frequent with remimazolam (17.78% vs. 59.42%; RR, 0.30; 95% CI, 0.18-0.49; < 0.001). Respiratory depression (3.70% vs. 26.09%; RR, 0.14; 95% CI, 0.04-0.53; = 0.004) and hypotension (8.15% vs. 41.30%; RR, 0.20; 95% CI, 0.09-0.42; < 0.001) were also lower with remimazolam. Remimazolam requirements remained stable across sessions (third vs. first: mean difference, 0.19 mg; 95% CI, -0.78 to 1.15; = 0.846). No significant between-group differences were observed in PSQI or AIS scores. CONCLUSION: Across three consecutive sedation sessions for interstitial brachytherapy, remimazolam was associated with fewer respiratory and hemodynamic adverse events than propofol, while sedative requirements remained stable across the three sessions. TRIAL REGISTRATION: Chinese Clinical Trial Registry (identifier: ChiCTR2500108294).

Annals of medicine 2026 Dec PubMed
04 Treating co-occurring alcohol use disorder and major depressive disorder: A systematic review of combination and multimodal pharmacotherapy. Sharif AF et al. 10.1111/ajad.70205
View abstract

BACKGROUND AND OBJECTIVES: Major depressive disorder (MDD) and alcohol use disorder (AUD) frequently co-occur and are associated with greater symptom severity and elevated suicide risk relative to either disorder alone, yet no pharmacological regimen is approved for the combined indication. This review systematically catalogs trials of combined and multimodal pharmacotherapy for comorbid AUD and MDD. METHODS: We searched PubMed/MEDLINE, Web of Science, and Google Scholar from inception through May 2024 for randomized or prospective open-label trials of combined pharmacotherapy, or single agents with dual-target activity, in adults with comorbid AUD and MDD. Seven trials (total N = 758) met inclusion criteria. RESULTS: Five trials tested combination regimens (naltrexone+acamprosate; naltrexone+disulfiram; naltrexone+sertraline; acamprosate+escitalopram; aripiprazole+escitalopram) and two tested single agents (vortioxetine; memantine vs. escitalopram). Naltrexone plus sertraline showed the strongest signal of dual benefit on drinking and depressive outcomes; acamprosate plus escitalopram was also promising, although based on a small pilot trial. Neither finding has been independently replicated, and the remaining regimens yielded mixed or modest results. DISCUSSION AND CONCLUSIONS: Converging dopaminergic, serotonergic, glutamatergic, opioidergic, and neuroimmune mechanisms support combined pharmacotherapy, but the evidence base remains thin, underpowered, and unreplicated. Available evidence and current integrated-care approaches favor concurrent rather than sequential treatment of AUD and MDD, although the evidence supporting specific pharmacological combinations remains limited. SCIENTIFIC SIGNIFICANCE: This is among the first reviews to integrate combination-pharmacotherapy trials with emerging multimodal single agents for comorbid AUD/MDD, and to map proposed mechanisms onto specific drug pairings, providing a framework for prioritizing future biologically stratified trials.

The American journal on addictions 2026 Oct 4 PubMed
05 Autoimmune adrenalitis in adolescents in Germany: a series of 4 cases. Pudig L et al. 10.1515/jpem-2026-0187
View abstract

OBJECTIVES: This case report summarises clinical findings in four adolescents (aged 14-17 years) diagnosed with autoimmune adrenalitis at a German University Children's Hospital between 2019 and 2025. CASE PRESENTATION: Clinical presentation varied and included fatigue, arterial hypotension, depressive symptoms, hyperpigmentation of the skin, and in one case acute kidney failure associated with acute viral infection. All patients showed hyponatraemia, reduced cortisol levels in serum and elevated adrenocorticotropic hormone concentrations at diagnosis. Autoimmune adrenalitis was confirmed in all patients by the presence of autoantibodies against the adrenal cortex. Interestingly, three of the four cases were diagnosed within a period of only 18 months. CONCLUSIONS: Our case series of autoimmune adrenalitis may suggest a potential increase  in the annual incidence among adolescents. The clinical diversity of symptoms at diagnosis ranging from depression to acute kidney failure was striking. Since delayed diagnosis may lead to life-threatening complications, awareness of clinical variability is essential for physicians to achieve timely diagnosis. Cortisol levels should be routinely measured in patients with unclear fatigue and hyponatraemia.

Journal of pediatric endocrinology & metabolism : JPEM 2026 Oct 5 PubMed
06 Depression, not stroke, is associated with greater expressive suppression while emotion identification is preserved. Ruiz-García Á et al. 10.1080/13803395.2026.2743149
View abstract

INTRODUCTION: Stroke is followed both by frequent depression and by reported alterations in emotional processing, yet these are rarely examined jointly, leaving it unclear whether emotional disturbances reflect the lesion or the concurrent depression. We aimed to separate the contributions of depression and of mild right-hemisphere stroke to two distinct components of socioemotional functioning: habitual emotion regulation and facial emotion identification. METHOD: Sixty adults were studied in a 2 × 2 design crossing Stroke (survivors of mild right-hemisphere ischemic stroke with complete functional recovery, modified Rankin Scale = 0, vs. stroke-free) and Depression (clinically diagnosed vs. absent). Habitual regulation was assessed with the Emotion Regulation Questionnaire (cognitive reappraisal, expressive suppression) and identification with a six-emotion forced-choice task. Data were analyzed with factorial analyses of variance, with covariate-adjusted and non-parametric confirmation, and with a dimensional analysis relating depressive symptom severity to each outcome. RESULTS: Depression, not stroke, was the principal correlate of habitual regulation. Participants with depression reported greater expressive suppression than those without (F = 7.50,  = .008, partial η = .12; Cohen's d = 0.74), independently of stroke and robust to adjustment for age and cognition. The parallel effect on reappraisal was directionally consistent but non-significant. Dimensionally, symptom severity correlated with suppression only. Facial emotion identification was preserved and did not differ across groups, with no Stroke × Depression interaction on any outcome. Stroke effects that were large in our earlier, less fully recovered sample were absent here. CONCLUSIONS: In well-recovered right-hemisphere stroke, depressive status rather than the lesion was associated with greater habitual reliance on expressive suppression, whereas emotion identification was intact. When emotional difficulties arise in such patients, concurrent depression rather than the lesion may warrant primary clinical attention. Given the modest sample and absence of lesion imaging, findings are provisional and require severity-stratified, imaging-informed replication.

Journal of clinical and experimental neuropsychology 2026 Oct 4 PubMed
07 Sexual orientation identity change and psychological distress among college students in Suzhou, Jiangsu, China: a longitudinal repeated-measures study. Yu C et al. 10.1080/13691058.2026.2737185
View abstract

In China, few longitudinal studies have examined sexual orientation identity change and psychological distress during late adolescence. From 2020 to 2021, 481 college students in Suzhou, Jiangsu, China, completed an average of 2.1 follow-up surveys (range: 1-3), yielding 1008 person-periods for potential change. Between any two successive surveys, there were four possible states involving heterosexual (Het) and sexual minority (SM) identity labels: static Het → Het, static SM → SM, Het → SM and SM → Het. Across all follow-up waves, seven distinct participant-level patterns were observed: static heterosexual, static sexual minority, Het → SM, SM → Het, Het → SM → Het, SM → Het → SM and SM → Het → SM → Het. Depressive and anxiety symptoms were assessed with the Patient Health Questionnaire-4. Overall, 13.5% of participants changed their reported sexual orientation identity label at least once. Multiple identity changes occurred in 4.3% of participants. Among men, Het → SM identity label periods were associated with more depressive symptoms and experience of shame/embarrassment compared to static heterosexual periods. Psychological distress associated with sexual orientation identity change likely reflects the heteronormative social environments in which these identity processes unfold, rather than identity fluidity itself.

Culture, health & sexuality 2026 Oct 4 PubMed
08 Executive functions are independently associated with health-related numeracy and self-perceived health literacy in applied contexts in healthy adults. Guzman T et al. 10.1080/13803395.2026.2743148
View abstract

INTRODUCTION: Over a third of U.S. adults struggle with health literacy, which broadly describes the ability to access, understand, and use health-related information. Conceptual models highlight the importance of cognitive functions in health literacy, but limited empirical work has carefully examined the extent to which various aspects of cognition uniquely contribute to different dimensions of health literacy. METHOD: Participants in this retrospective, harmonized study included 312 healthy adults who completed a battery of well-validated cognitive tests that measured their general fund of knowledge, attention, declarative memory, and executive functions (;). Participants also completed a performance-based measure of health-related numeracy (i.e., Expanded Numeracy Scale) and questionnaires assessing self-perceived health literacy in applied contexts (i.e., Brief Health Literacy Screening and eHealth Literacy Scale). RESULTS: After accounting for the influence of sociodemographics and general fund of knowledge parallel hierarchical regressions showed that measures of executive functions and memory explained a significant amount of variance in health-related numeracy and measures of executive functions explained a significant, but modest, amount of variance in self-perceived health literacy in applied contexts after accounting for the influence of sociodemographics and general fund of knowledge. CONCLUSIONS: Findings suggest that executive functions (i.e. generativity and cognitive flexibility) play a unique role in some aspects of personal health literacy among healthy adults. Future experimental studies might further dissect the role of executive functions in the expression and management of health literacy in at-risk clinical populations.

Journal of clinical and experimental neuropsychology 2026 Oct 4 PubMed
09 Gut-Brain Axis in Comorbid Constipation and Mood Disorders: Navigating the Efficacy-Tolerability Dilemma Through Emerging Evidence and Future Directions. Tu M et al. 10.2147/IJGM.S634121
View abstract

BACKGROUND: The comorbidity of constipation and mood disorders (anxiety/depression) creates a vicious cycle of symptom superposition and treatment resistance. The persistent "efficacy-tolerability" dilemma-whereby effective treatment for one condition may exacerbate the other-remains unresolved. METHODS: This narrative review is based on a systematic search of PubMed, Embase, and Cochrane Library (2015-2026), focusing on epidemiology, gut-brain axis mechanisms, pharmacotherapy limitations, and emerging strategies. The search formula was: ("constipation" OR "functional constipation") AND ("mood disorders" OR "anxiety" OR "depression") AND ("gut-brain axis" OR "microbiota" OR "pharmacotherapy"). RESULTS: Constipation and mood disorders show a bidirectional association, supported by recent Mendelian randomization studies. Pathogenesis involves central/enteric nervous system dysfunction, microbiota imbalance, and inflammatory mediators. Conventional drugs (eg, selective serotonin reuptake inhibitors [SSRIs], stimulant laxatives) may worsen one condition while treating the other. Preliminary evidence suggests gut-brain axis-targeted therapies-including 5-hydroxytryptamine type 4 (5-HT4) receptor agonists, psychobiotics, and multidisciplinary team models-may improve outcomes, but most findings remain exploratory. CONCLUSION: Overcoming the dilemma requires mechanism-oriented drug selection, optimized combination regimens, and individualized management. Future efforts should accelerate multi-target drug trials, multi-omics-based precision models, and multidisciplinary team implementation. The evidence base remains limited, with few large randomized controlled trials specifically targeting the comorbid population. Readers should interpret all quantitative estimates with caution, as they derive from heterogeneous study designs.

International journal of general medicine 2026 PubMed
10 Experimental Study on Anxiolytic and Antidepressant Effects of Zhi-Chi-Jie-Yu Granules in CUMS Mice and Prediction of Underlying Molecular Mechanisms. Luo Y et al. 10.2147/NDT.S641398
View abstract

OBJECTIVE: This study investigated the in‑vivo pharmacological effects of Zhi-Chi-Jie-Yu Granules(ZCK) on CUMS‑induced anxiety‑ and depression‑like behaviors in mice. Post‑hoc exploratory analyses including network pharmacology and molecular docking were further performed to generate potential mechanistic hypotheses for its anti‑depressant action. METHODS: An anxiety‑depression model was established in ICR mice via chronic unpredictable mild stress (CUMS) combined with solitary housing. Mice were divided into six groups (n=10): blank control, model, fluoxetine, and ZCK low‑, medium‑, and high‑dose groups. Behavioral changes were assessed by secondary‑auxiliary (SPT), together with FST, TST, OFT and EPM. Serum inflammatory cytokines and hippocampal neurotransmitters (5‑HT, NE) were measured by ELISA, and hippocampal pathological damage was observed by HE staining. UPLC‑Q‑TOF‑MS was used to characterize the chemical profile of ZCK. Non‑targeted serum metabolomics, network pharmacology, and molecular docking were integrated to predict targets and pathways. RESULTS: ZCK significantly alleviated CUMS‑induced depressive‑ and anxiety‑like behaviors (P < 0.05 or P < 0.01). It downregulated serum pro‑inflammatory cytokines (IL‑6, TNF‑α), increased hippocampal 5‑HT and NE levels, and attenuated neuronal damage. UPLC‑Q‑TOF‑MS identified 39 core components. Metabolomics revealed 56 differential metabolites, mainly enriched in alanine‑aspartate‑glutamate and arachidonic acid metabolism. Network pharmacology predicted 410 overlapping targets, and the top‑10 core targets contained TP53, AKT1, STAT3, SRC, TNF and others. Considering our experimental findings on neuroinflammation, inflammatory‑related key targets (SRC, TNF, IL-6, NF‑κB and IL-1B) were selected for subsequent molecular‑docking verification. Molecular‑docking simulations suggested potential binding interactions between core components and key targets (binding energies <-5.0 kcal/mol). CONCLUSION: ZCK exerts anti‑anxiety and antidepressant effects in CUMS mice, accompanied by reduced peripheral neuroinflammation and improved hippocampal neurotransmitter levels. Multi‑omics and network‑pharmacology analyses further predict potential multi‑dimensional regulatory candidates, including neuroinflammation‑related signaling, neurotransmitter homeostasis and metabolic perturbation. These computational hypotheses require further protein‑level experimental validation. This study provides preliminary in‑vivo evidence for ZCK and an integrated methodological reference for TCM compound research.

Neuropsychiatric disease and treatment 2026 PubMed
11 Chronic Pain and Newly Reported Frequent Feelings of Depression: A Nationally Representative Longitudinal Study in 2019-2020. Zang H et al. 10.2147/JPR.S625218
View abstract

PURPOSE: Nationally representative longitudinal evidence on the association of chronic pain and pain-related activity limitation with newly reported frequent feelings of depression remains limited. We examined the association using the 2019-2020 National Health Interview Survey follow-back cohort. METHODS: The longitudinal cohort used nationally representative data from the 2019-2020 National Health Interview Survey to examine the relationship between chronic pain and newly reported frequent feelings of depression among US adults. The primary outcome was newly reported frequent feelings of depression in 2020. Weighted modified Poisson regression models with robust standard errors were used to estimate risk ratios, adjusting for demographic and health-related covariates. RESULTS: Among adults with chronic pain and nonchronic pain in 2019, the cumulative incidence of newly reported frequent feelings of depression in 2020 was 9.0% (95% CI, 7.3-10.7%) and 5.5% (95% CI, 4.4-6.5%), respectively. Chronic pain was associated with a higher likelihood of newly reported frequent feelings of depression after adjusting for demographic and health-related characteristics (adjusted risk ratio, 2.32 [95% CI, 1.71-3.15]). A similar association was observed between high-impact chronic pain and increased likelihood of newly reported frequent feelings of depression (adjusted risk ratio, 2.86 [95% CI, 1.96-4.16]). CONCLUSION: We found that chronic pain exposure was associated with a higher likelihood of newly reported frequent feelings of depression. These findings suggest that psychological treatment should also be considered in the management of chronic pain.

Journal of pain research 2026 PubMed
12 Comparative Analysis of Antidepressant Mechanisms and Side Effects: Network Pharmacology and Molecular Docking Study of Amitriptyline, Mirtazapine, and Escitalopram for Treating Major Depressive Disorder. Zhuo C et al. 10.1155/da/6981320
View abstract

BACKGROUND: Amitriptyline, mirtazapine, and escitalopram are effective antidepressants for treating major depressive disorder (MDD). Our study aimed to use computational biology to understand the mechanisms for the similarities and differences in efficacies and side effects of these drugs. METHODS: Potential targets for MDD and the three drugs were obtained using public databases. Venn diagrams and protein-protein interaction (PPI) networks were constructed. Drug-target-pathway (D-T-P) networks were built using Cytoscape, and core targets were filtered using CytoNCA and CytoHubba plugins. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted using the Database for Annotation, Visualization, and Integrated Discovery. Ligand compounds and receptor proteins were processed with PyMOL and AutoDock. The binding of amitriptyline, mirtazapine, and escitalopram with core targets was predicted by molecular docking using AutoDock Vina. The results were visualized using PyMOL and protein-ligand interaction profiler (PLIP). RESULTS: Forty-eight overlapping targets and 66, 50, and 30 individual targets for MDD treatment were identified for amitriptyline, mirtazapine, and escitalopram, respectively. Critical pathways included "Neuroactive ligand-receptor interaction," "Calcium signaling pathway," and "Serotonergic synapse." Key targets, indicating a wide range of effects on cellular activities and signaling mechanisms, included D(2) dopamine receptor (DRD2), CYP2D6, monoamine oxidase type B (MAOB), solute carrier family 6 member 3 (SLC6A3), solute carrier family 6 member 4 (SLC6A4), 5-hydroxytryptamine receptor 2C (HTR2C), and CHRNA4. MAOB had the highest binding affinity with amitriptyline, followed by SLC6A4 and DRD2. Binding stability was enhanced by salt bridges and π-stacking interactions. Mirtazapine formed strong binding affinities with HTR2C, SLC6A4, and CHRNA4 through hydrogen bonds and π-stacking interactions. Escitalopram exhibited the highest affinity for SLC6A3, followed by HTR2C. CONCLUSION: All three drugs regulated serotonin, norepinephrine (NE), and dopamine, but target specificity, pathways, and binding patterns differed. Amitriptyline exhibited stronger antidepressant effects and broader mechanisms but a higher risk of side effects. Mirtazapine's dual mechanism regulates broad targets with reliable efficacy and fewer side effects. Escitalopram selectively acts on serotonin-related targets, with narrow actions and potentially fewer side effects. These findings align with the clinical profiles of the antidepressant efficacy and side effects.

Depression and anxiety 2026 PubMed
13 A Randomized Controlled Trial of a Digital Stepped-Care Program to Reduce Anxiety and Depressive Symptoms Among Long-Term Care Workers With Psychological Distress: The REPICAL Study. González-Spinoglio L et al. 10.1155/da/5875889
View abstract

BACKGROUND: Long-term care workers (LTCWs), encompassing those in long-term care facilities and home-care settings, constitute a particularly vulnerable population to psychological distress. This study aimed to evaluate the effectiveness of a digital stepped-care program, adapted from two World Health Organization (WHO) psychological interventions-Doing What Matters in Times of Stress (DWM) and Problem Management Plus (PM+)-in reducing anxiety and depressive symptoms among LTCWs. METHODS: A parallel-group randomized controlled trial was conducted. Participants were LTCWs from Catalonia (Spain) experiencing psychological distress (Kessler Psychological Distress Scale, K10 ≥ 16). All participants received Psychological First Aid (PFA), and those in the intervention group subsequently received the digital stepped-care program: DWM as step 1, and if psychological distress persisted (K10 ≥ 16), PM + as step 2. The primary outcome was the between-group difference in self-reported depressive and anxiety symptoms at week 21 (2-month post-program follow-up), measured using the Patient Health Questionnaire-Anxiety and Depression Scale (PHQ-ADS). Secondary outcomes included depressive and anxiety symptoms measured separately, post-traumatic stress disorder (PTSD) symptoms, and health-related quality of life (HR-QoL; measured using PHQ-9, 7-item Generalized Anxiety Disorder [GAD-7] scale, PCL-5, and EuroQol 5-dimensional descriptive system-5-level [EQ-5D-5L], respectively). RESULTS: Between October 2022 and May 2024, 165 participants were randomized (intervention:  = 83; control:  = 82). At week 21, depressive and anxiety symptoms were significantly lower in the intervention group, with moderate to large effect sizes (mean difference = 4.2, 95% CI: 1.1-7.3; Standardized effect size [SES] = 0.8, 95% CI: 0.1-1.4). Secondary outcomes also showed significantly greater improvement in the intervention group, except for HR-QoL, for which no differences were found. CONCLUSIONS: This study provides evidence supporting the effectiveness of a digital and scalable stepped-care program to support LTCWs' mental health. These robust findings may inform occupational and public health strategies for supporting LTCWs' experiencing psychological distress. ClinicalTrials.gov identifier: NCT05526235.

Depression and anxiety 2026 PubMed
14 Interaction between mental health conditions and hip fracture on the 30-day risk of infection among older adults: a Danish matched cohort study. Moestrup LJ et al. 10.1007/s41999-026-01623-7
View abstract

PURPOSE: Infections are a frequent complication following hip fracture (HF) surgery. Although approximately 30% of patients undergoing HF surgery have a mental health condition, its potential interaction on the risk of post-operative infection remains uncertain. METHODS: Using Danish nationwide registries, we included a cohort of patients with HF aged ≥ 65 years operated during 2004-21 (n=100 335) and an age- and sex-matched comparison cohort from the general population without HF at the index date (n=498 943). Mental health conditions were identified using diagnosis codes F00-F48. Outcomes were hospital-treated infections (H-TIs) and hospital- or community-treated infections (HC-TIs) within 30 days after surgery. Cumulative incidence with 95% confidence intervals (CI) was estimated with death as competing risk. Interaction was assessed on an absolute and relative scale. RESULTS: The highest incidence of H-TIs was observed among patients with HF and mood disorders (18.1%, 95% CI: 17.3-19.0) and comparators with anxiety disorders (2%, 95% CI: 1.8-2.5). Among patients with HF, the highest incidence of HC-TIs was in those with dementia (43.0%, 95% CI: 42.2-43.9). Likewise, comparators with dementia had the highest incidence of HC-TIs (18.4%, 95% CI: 17.9-18.8). Across mental health condition categories, attributable fractions ranged from 1.1% to 32.3% for H-TIs and 10.8%-19.7% for HC-TIs. The strongest synergistic effect was observed in patients with psychoactive substance use for both H-TIs and HC-TIs. CONCLUSIONS: Patients with HF and mental health conditions are at higher risk of infection than comparators. Mental health conditions and HF interact synergistically, which increases the infection risk by more than 30%, highlighting the need for targeted treatment for patients with HF and mental health conditions.

European geriatric medicine 2026 Oct 3 PubMed
15 Detransition, Posttraumatic Stress Disorder, and Moral Injury. Clayton A et al. 10.1007/s10508-026-03669-x
View abstract

There are increasing reports of individuals who, after undergoing medical gender-affirming treatments (GAT) for gender incongruence/gender dysphoria, subsequently detransition and/or express regret regarding these interventions. Although detransition experiences are heterogeneous, some individuals who detransition describe substantial adverse physical consequences and psychological distress resulting from the GAT they received. The purpose of this article is to assist mental health professionals in their understanding and conceptualizing of detransition experiences within the existing Diagnostic and Statistical Manual of Mental Disorders (DSM) framework. It is posited that a diagnosis of posttraumatic stress disorder, as delineated in the most recent text revision of the DSM (DSM-5-TR) (American Psychiatric Association, 2022), may be applicable for some individuals who have detransitioned. Furthermore, the relevance of the moral injury concept-recently incorporated into the DSM-5-TR under code Z65.8 (American Psychiatric Association, 2025)-as it pertains to this population, is discussed.

Archives of sexual behavior 2026 Oct 3 PubMed
16 Serotonergic Toxicity and Hyponatremia Associated with Antidepressant Therapy: The Pivotal Role of SIADH. Morena D et al. 10.1007/s40261-026-01599-z
View abstract

Serotonin syndrome (SS) and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) are well-recognized adverse drug reactions (ADRs) associated with serotonergic agents, particularly antidepressants. Although traditionally regarded as distinct clinical entities, accumulating evidence suggests that SIADH may represent a key pathophysiological link between serotonergic toxicity and acute hyponatremia, thereby explaining their frequent clinical overlap and, in some cases, severe or fatal outcomes. Excessive serotonergic activity can stimulate hypothalamic pathways regulating arginine vasopressin secretion, resulting in euvolemic hyponatremia and hyponatremic encephalopathy while simultaneously producing the characteristic neuromuscular, autonomic, and mental status abnormalities of SS. This narrative review examines the shared pathophysiological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic implications of SS and SIADH-associated hyponatremia. A comprehensive literature search was conducted, including reviews, pharmacological studies, and case reports involving antidepressants, opioids, antihistamines, nutraceuticals, and emerging serotonergic agents such as ketamine, esketamine, and psilocybin. Particular attention is given to medication combinations, over-the-counter medications, and dietary supplements that may increase serotonergic burden through pharmacodynamic and pharmacokinetic interactions. The review highlights SIADH as the "thin red line" connecting serotonergic excess with rapid-onset hyponatremia and emphasizes the diagnostic complexity arising from the overlap between neurological manifestations of SS and metabolic encephalopathy secondary to hyponatremia. It also underscores the importance of a systematic diagnostic evaluation of suspected SIADH, including assessment of serum and urinary osmolality and urinary sodium concentration. In published case reports, the absence of urinary osmolality measurements frequently precludes confirmation of SIADH according to established diagnostic criteria, limiting the diagnosis to a possible or probable form rather than a definitive one. Greater awareness of this pathophysiological interplay is essential for early recognition, accurate differential diagnosis, risk stratification, and prevention of severe outcomes through careful medication review, appropriate laboratory evaluation, electrolyte monitoring, and prompt discontinuation of offending agents.

Clinical drug investigation 2026 Oct 3 PubMed
17 Pulmonary embolism response team consulting practices and in-hospital outcomes in intermediate-high and high-risk pulmonary embolism. Cho LD et al. 10.1007/s11239-026-03405-1
View abstract

The goal of this analysis is to evaluate factors associated with PERT consultation and to determine if PERT consultation was associated with differences in outcomes for patients with intermediate-high and high-risk PE. All intermediate-high or high-risk PE cases at a single institution from 2016 to 2019 were reviewed. Outcomes were in-hospital mortality, length of stay (LOS), and moderate/severe bleeding. Clinical characteristics, imaging findings, and outcomes were compared between cases with and without PERT consultation. 335 cases were included, with PERT consulted in 52%. PERT was consulted more in cases with increased right ventricle (RV) size and depressed RV function (both p < 0.0001). PERT was consulted more for saddle (85.5%, p < 0.0001) and less for segmental (39.0%, p < 0.0001) PE. Use of catheter-based therapies, such as catheter-directed thrombolysis (23.0% vs. 1.9%, p < 0.001), was higher within the PERT group. Cases with PERT involvement had a shorter mean LOS (13 vs. 24 days), lower in-hospital mortality (8.1% vs. 21.0%), and less bleeding (9.8% vs. 21%) (all p < 0.004); there was no difference in PE-related mortality (p = 0.51). In multivariate analyses, PERT consultation was a predictor of lower in-hospital mortality (OR 0.30, CI 0.15-0.64, p = 0.002), bleeding (OR 0.43, CI 0.22-0.85, p = 0.01), and LOS (OR 0.38, CI 0.22-0.67, p = 0.0007). PERT was consulted more in cases of central PE and cases with greater signs of RV strain. PERT was associated with increased use of catheter-based therapies, lower in-hospital mortality and bleeding, and a shorter LOS.

Journal of thrombosis and thrombolysis 2026 Oct 3 PubMed
18 The safety and tolerability of opicapone in elderly Parkinson's disease patients: a real-world, multicenter, retrospective study. De Carolis L et al. 10.1007/s00702-026-03284-z
View abstract

Opicapone (OPC) is an effective add-on medication for motor fluctuations in Parkinson's disease (PD), with a favorable safety and tolerability profile. Elderly PD patients are a great proportion of the real-world PD population, often underrepresented in clinical trials. This multicenter, retrospective, longitudinal study aimed to assess the real-world safety and tolerability of OPC in PD patients aged ≥ 65 years. Clinical-demographic data were collected at OPC initiation (T0) and at the last follow-up visit (T1). OPC-related adverse events (AEs) and reasons for discontinuation were recorded. Patients were compared according to age and treatment continuation. Logistic regression analyses were used to evaluate association between baseline features and occurrence of AEs and discontinuation. One-hundred and one elderly PD patients were included and followed up for 20.6 ± 18.8 months after OPC initiation. Overall, 49 patients (48.5%) reported AEs, and OPC was discontinued in 29 (28.7%) within 9.4 ± 15.3 months, with neuropsychiatric and cardiovascular/autonomic AEs being the most common reasons. Patients aged ≥ 75 years reported greater disease severity and frequency of AEs compared to younger patients, but similar discontinuation rates at follow-up. At T1, OPC discontinuers exhibited greater motor impairment and a lower total levodopa equivalent dose. Univariate analyses showed that age, disease stage, and comorbidity burden were significantly associated with AEs occurrence. In the multivariable analysis, disease stage remained the only significant baseline feature associated with AEs. OPC was generally well tolerated in this cohort of real-world elderly PD patients. Larger, prospective studies are warranted.

Journal of neural transmission (Vienna, Austria : 1996) 2026 Oct 3 PubMed
19 Anastasis: an unwelcome guest in cancer therapy. Luo Y et al. 10.1007/s10495-026-02455-3
View abstract

Anastasis is a newly identified cellular recovery process that enables cells to regain viability after progressing into execution-phase apoptosis. In cancer, this process may allow tumor cells to survive transient cytotoxic stress and subsequently acquire more aggressive phenotypes, including enhanced migration, invasion, and resistance to therapy. Although anastasis has attracted increasing attention, its biological significance and contribution to cancer progression remain incompletely understood. In this review, we summarize the defining features and biological processes of anastasis and critically evaluate current evidence linking post-apoptotic recovery to cancer-associated phenotypes, including apoptosis regulation, metastasis, angiogenesis, oxidative-stress adaptation, and epithelial-mesenchymal transition. We further discuss molecular pathways implicated in anastatic recovery and examine potential therapeutic strategies aimed at limiting post-apoptotic survival in cancer cells. Finally, we highlight major challenges in the field, including the need for more specific biomarkers, physiologically relevant in vivo models, and direct clinical validation, and outline key unresolved questions that should guide future investigation.

Apoptosis : an international journal on programmed cell death 2026 Oct 3 PubMed
20 Role of self-management among virally suppressed and unsuppressed adolescents living with HIV in Dar es Salaam, Tanzania. Siril HN et al. 10.1080/09540121.2026.2737591
View abstract

Globally, significant progress toward ending the HIV/AIDS epidemic includes advances in HIV treatment, converting a fatal infection to a chronic disease. Adolescents living with HIV (AWHIV) continue to underachievein HIV viral suppression (VS) needed to remain healthy. This cross-sectional study aimed to examine the role of self-management and related factors in VS among AWHIV aged 15-19 years in Dar es Salaam, Tanzania. A total of 658 AWHIV from ten large HIV care and treatment sites were assessed on HIV-related self-management, depression, HIV stigma, physical quality of life and social support. HIV viral load was abstracted from clinical records. Generalized linear models were used to examine unadjusted and adjusted mean differences in self-management scores between the two groups. Over half of the AWHIV, 403(78%), had achieved VS. Overall, sub-scale self-management scores did not differ significantly between groups ( > .05); however, three self-management items significantly differed by VS status: health self-efficacy ( = 0.049), life ambitions/goals ( = 0.031) and ART administration knowledge ( = 0.044). Adjusted models attenuated self-efficacy and ambition differences while ART knowledge differences persisted ( = 0.005). Physical quality of life, social support and stigma significantly moderated relationships between self-management items and VS. These findings suggest that focusing on targeted self-management behaviors may provide a more accurate understanding of their influence on VS than aggregated self-management scores.

AIDS care 2026 Oct 3 PubMed
21 Remimazolam Versus Propofol During Hysteroscopy: A Systematic Review And Meta-Analysis of Nine Randomized Controlled Trials. Boudjelal A et al. 10.1016/j.clinthera.2026.09.004
View abstract

PURPOSE: To compare the efficacy and safety of remimazolam (RMZ) versus propofol during hysteroscopy. METHODS: A systematic review and meta-analysis synthesizing evidence from randomized controlled trials (RCTs) obtained from PubMed, Google Scholar, EMBASE, CENTRAL, Scopus, and Web of Science until February 2025. We pooled dichotomous outcomes and continuous outcomes using relative risk (RR) and standardized mean difference, respectively, with a 95% confidence interval (CI). FINDINGS: Nine RCTs and 1164 patients were included. RMZ was significantly associated with decreased incidence of injection pain (RR = 0.07; with 95% CI, [0.02, 0.20]; P = 0.001), hypotension (RR = 0.33; with 95% CI, [0.22, 0.50]; P = 0.001), and low SpO₂/respiratory depression (RR = 0.26; with 95% CI, [0.18, 0.38]; P = 0.001). However, RMZ was significantly associated with an increased incidence of hiccough (RR = 10.37; with 95% CI, [2.94, 36.62]; P = 0.001), with no significant difference between both groups regarding bradycardia (RR = 0.32; with 95% CI, [0.08, 1.18]; P = 0.09), and body movement (RR = 1.17; with 95% CI, [0.95, 1.44]; P = 0.15). Additionally, there was no significant difference between the 2 groups regarding sedation success (P = 0.83), recovery duration (P = 0.05), and total procedural duration (P = 0.07). IMPLICATIONS: RMZ may provide a safer alternative to propofol during hysteroscopy, with similar procedural outcomes and fewer injection-related and cardiorespiratory adverse events.

Clinical therapeutics 2026 Oct 3 PubMed
22 Differential Contributions of Internalized Racism Facets on Psychological Distress. Quiles JRG et al. 10.1891/JCP-2025-0049
View abstract

This study examined the relative contributions of various facets of internalized racism (IR) to anxious arousal and depressive symptoms. A racially diverse sample of 205 U.S.-based racial/ethnic minority adults ( = 27.96, 60% female, 55.6% Black/African American, 18.5% Asian, 14.6% multiracial, and 11.3% other) completed validated measures of IR, anxiety, and depression. Hierarchical regressions were conducted to assess the unique effects of four IR facets across affective and cognitive dimensions: emotional reactions (affective) with group devaluation, adoption of dominant cultural standards, and patterns of thinking (cognitive), above and beyond sociodemographic information. Global IR was significantly and positively associated with both anxiety and depression, with affective facets being significantly associated with anxiety, whereas the cognitive process of group devaluation was significantly associated with both anxiety and depressive symptomatology. These findings suggest that specific cognitive and affective facets may be implicated in the development of internalizing symptoms among minoritized individuals, particularly shame-based emotional responses and intragroup devaluation. Clinical implications suggest that cognitive restructuring and acceptance-based approaches may help address maladaptive beliefs and emotions tied to racial identity. This study extends the existing literature by exploring how cognitive and affective forms of IR may differentially relate to anxious and depressive presentations, providing direction for refining theoretical models of race-related stress and psychopathology.

Journal of cognitive psychotherapy 2026 Oct 3 PubMed
23 Investigating the Role of Stress in Misophonia: Stress as a Clinical Correlate and Its Influence on Treatment Outcomes. Woolley MG et al. 10.1891/JCP-2026-0015
View abstract

Misophonia is a sound intolerance disorder characterized by strong emotional and physiological reactions to specific everyday sounds. Emerging research suggests that stress may play an important role in misophonia, yet little work has examined whether stress uniquely contributes to misophonia severity or influences treatment response. The present study examined the role of stress in misophonia using data from a randomized clinical trial of treatment-seeking adults ( = 60) comparing acceptance and commitment therapy and progressive relaxation training. First, we examined whether stress symptoms were uniquely associated with misophonia severity and impairment at baseline when accounting for anger, disgust propensity and sensitivity, anxiety, depression, obsessive-compulsive symptoms, and demographic variables. Second, we examined whether baseline stress influenced trajectories of change in misophonia outcomes over time and whether these differed across treatment conditions. Results suggested that, at baseline, stress symptoms were the only clinical correlate that uniquely predicted misophonia symptom severity and misophonia-related impairment. Baseline stress was also associated with differences in treatment trajectories, such that individuals reporting lower stress showed greater improvement in misophonia symptoms and impairment by the 6-month follow-up compared with those with higher stress. However, stress did not interact with treatment condition; both treatments performed equally regardless of stress levels. These findings suggest that stress may represent a broader psychological process associated with misophonia severity and the durability of treatment gains.

Journal of cognitive psychotherapy 2026 Oct 3 PubMed
24 Sex differences in self-reported executive function, anxiety and depression symptoms among young adults in substance use disorder treatment. Scarth M et al. 10.1016/j.josat.2026.210134
View abstract

INTRODUCTION: Substance use disorders (SUD) are more prevalent among males than females, but recent evidence suggests this gap is narrowing. This shift highlights the need to better understand sex differences in cognitive and psychological characteristics among individuals with SUD. This study aims to explore sex differences in self-reported executive functioning and psychological distress and their associations with severity of SUD symptoms among young adults in SUD treatment. METHODS: Data were collected from 97 inpatients (mean age = 23.3 ± 2.6 years) at a SUD treatment center for young adults in Oslo, Norway. Within two weeks of admission, participants completed questionnaires evaluating alcohol and drug-related problems, executive functioning, and psychological distress at intake. These measures were compared between males and females using Welch's t-tests, and the relationships between psychological distress and executive function and severity of drug-related problems were evaluated using Spearman's correlations and linear regression in the whole sample and within each sex. RESULTS: Both males (n = 65) and females (n = 32) reported high levels of polysubstance use. A majority of the sample scored above the clinical cut-off levels for executive dysfunction (71%) and psychological distress (85%). Females reported more executive function challenges than males in several areas including emotional control (p < 0.001) and working memory (p = 0.003). Regression analyses demonstrated associations between increased executive dysfunction and psychological distress and severity of drug use disorder in the whole sample and among males. CONCLUSION: These findings emphasize the high psychiatric comorbidity among SUD patients, with females showing elevated executive dysfunction alongside anxiety symptoms. Females in SUD treatment may represent a more clinically severe subgroup. Routine assessment of executive functioning is warranted, and future studies should clarify these associations and their relevance for targeted interventions.

Journal of substance use and addiction treatment 2026 Oct 3 PubMed
25 Serious mental illness and outcomes in inpatient detoxification and rehabilitation: A retrospective cohort study. Lynch ST et al. 10.1016/j.josat.2026.210131
View abstract

BACKGROUND: Substance use disorders frequently co-occur with severe mental illness (SMI), and individuals with co-occurring diagnoses often experience greater clinical complexity and poorer treatment outcomes. However, little is known about treatment engagement and outcomes among patients with SMI receiving inpatient addiction treatment in detoxification and rehabilitation settings. METHODS: This retrospective cohort study examined patients admitted to an inpatient detoxification and rehabilitation unit at an urban academic behavioral health center between January 1 and March 31, 2024. SMI was defined as a history of a psychotic disorder, bipolar disorder, or prior psychiatric hospitalization. Sociodemographic characteristics, clinical history, treatment course, and post-discharge outcomes were extracted from the electronic medical record. Groups with and without SMI were compared using chi-square and independent-samples t-tests. Time to readmission was evaluated using Kaplan-Meier survival analysis. Multivariable logistic regression examined associations with readmission within one year. RESULTS: Among 198 patients, 90 (45.5%) met criteria for SMI. Compared with those without SMI, patients with SMI had higher rates of trauma, violence history, unemployment, and prior detoxification or rehabilitation admissions. Despite these differences, there were no significant group differences in detoxification completion, transition to rehabilitation, rehabilitation completion, or length of stay. Readmission rates within one year did not differ between groups in bivariable analyses. In the primary adjusted analysis, SMI was associated with lower odds of readmission (OR = 0.49, 95% CI 0.25-0.98), while greater prior detoxification or rehabilitation utilization was associated with increased readmission risk (OR = 1.04 per admission). The association between SMI and readmission was attenuated in sensitivity analyses. CONCLUSIONS: Patients with SMI admitted to inpatient detoxification and rehabilitation demonstrated greater psychosocial complexity but similar treatment engagement compared with patients without SMI. These findings suggest that structured inpatient addiction treatment settings may support comparable engagement in care among individuals with co-occurring severe psychiatric illness.

Journal of substance use and addiction treatment 2026 Oct 3 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Mental Health & Depression
  • Week: September 28 – October 5, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 7:35 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —